Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vlad Vitoc
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- 0.26
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.57
Financials
Net Income
$-7.94MEBITDA
$-7.57MFree Cash Flow
$-6.75MEPS (diluted)
$-0.13Shares Outstanding (diluted)
60.79M+471.6%Operating Expenses
$8.32MCash & Debt
$27.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.40M | $-0.70 |
| 2024 | $0.00 | $-23.25M | $-1.05 |
| 2023 | $0.00 | $-19.77M | $-1.49 |
| 2022 | $0.00 | $-15.77M | $-1.70 |
| 2021 | $0.00 | $-12.50M | $-1.18 |
| 2020 | $0.00 | $-6.64M | $-0.62 |
| 2019 | $0.00 | $-6.49M | $-0.61 |
Valuation
MAIAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·5d ago·Negative
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.
View source ↗ - Newsyoutube.com·7d ago·Neutral
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that looks like a ‘Muse'-style assistant for workplace use. He notes that the company's push suggests the focus is shifting from building the underlying AI technology to packaging it into tools that connect with day-to-day work and personal applications.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) a…
View source ↗ - Newsglobenewswire.com·14d ago·Positive
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biop…
View source ↗ - Newsglobenewswire.com·20d ago·Negative
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 1…
View source ↗ - Newsyoutube.com·24d ago·Negative
MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding PIMCO economist Tiffany Wilding said labor markets are no longer a major source of inflation pressure, pointing to broad measures of nominal wage inflation that have been decelerating. She argued that AI, demographic shifts, aging, and retirements are changing labor dynamics and keeping wage pressures modest.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster fea…
View source ↗ - Newsglobenewswire.com·50d ago·Negative
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $-0.13 per share
Typical surprise +15.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.13 vs $-0.11miss
- Mon, May 11$-0.14 vs $-0.18beat
- Mon, Mar 23$-0.08 vs $-0.13beat
- Fri, Nov 7$-0.27 vs $-0.19miss
- Mon, Aug 11$-0.18 vs $-0.24beat
- Fri, May 9$-0.16 vs $-0.18beat
Estimates and results for MAIA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MAIA officers and directors.
- Bought
- $2.5m
- Sold
- —
49 trades
0 trades
- Vitoc Vladboughtdirector, 10 percent owner, officer: Chief Executive Officer·73,000 @ $1.37·$100k·Sep 14, 2026·filing
- Guerrero Ramirobought
- Guerrero Ramirobought
- Guerrero Ramirobought
- Guerrero Ramirobought
- Guerrero Ramirobought
- Guerrero Ramirobought
- Vitoc Vladboughtdirector, 10 percent owner, officer: Chief Executive Officer·72,700 @ $1.39·$101k·Jun 1, 2026·filing
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MAIA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.